Roche Alzheimer's blood test pTau217 receives European CE mark

Roche announced on May 12 that its Elecsys plasma pTau217 test, co-developed with Eli Lilly, received the European CE mark. Unlike pTau181, it supports not only ruling out Alzheimer's pathology but also confirming it, reducing the burden of invasive CSF testing and brain imaging. CE-market launch is planned for July 2026.